9

“I certainly notice that it is somewhat difficult, in these times (…) to fund completely new parties, let’s say a start-up or perhaps some large parties that have little experience. At the moment, we are a little less willing to take a risk to invest in it. That has to do with, (…) that we really want to work towards real results.”—Publ1

10

“When we’re launching calls we need to know that there are researchers who would respond to those calls and we also in many cases need to know if there are products in development. So if we want to fund clinical trials of vaccines, we need to know if there are some products out there that could be included in proposals and in fact that is one of an issue for NTDs often that there are no new products coming through.”—Inter3